表紙
市場調查報告書

單株抗體的全球市場:2018年∼2022年

Global Monoclonal Antibodies Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 364925
出版日期 內容資訊 英文 115 Pages
訂單完成後即時交付
價格
Back to Top
單株抗體的全球市場:2018年∼2022年 Global Monoclonal Antibodies Market 2018-2022
出版日期: 2018年12月07日內容資訊: 英文 115 Pages
簡介

全球單株抗體市場預測直至2022年,將以約15%的CAGR(年複合成長率)擴大。

本報告提供全球單株抗體市場相關調查,彙整市場成長預測,各地區趨勢,市場趨勢與課題,主要供應商的競爭趨勢等資料。

第1章 摘要整理

第2章 本報告的調查範圍

第3章 調查手法

第4章 市場形勢

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第5章 開發平台分析

第6章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模與預測

第7章 波特的五力分析

第8章 各用途的市場分類

  • 各用途的分類
  • 各用途比較
  • 腫瘤學 - 市場規模與預測
  • 免疫學 - 市場規模與預測
  • 血液學 - 市場規模與預測
  • 其他 - 市場規模與預測
  • 市場機會:各用途

第9章 單株抗體的各種類的市場分類

  • 單株抗體的各種類的市場分類
  • 老鼠抗體
  • 人抗體
  • 人體化抗體
  • 嵌合抗體

第10章 客戶形勢

第11章 地區形勢

  • 地理區分
  • 地區比較
  • 南北美洲 - 市場規模與預測
  • 歐洲、中東、非洲地區 - 市場規模與預測
  • 亞太地區 - 市場規模與預測
  • 市場機會

第12章 決策架構

第13章 市場成長因素與課題

  • 市場成長因素
  • 市場課題

第14章 市場趨勢

第15章 業者情勢

  • 概要
  • 創造性破壞狀況

第16章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Merck

第17章 附錄

  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR21977

About this market:

Rise in the number of companies venturing into monoclonal antibodies space to drive market growth. To gain profits, the companies are investing huge amounts in the development of monoclonal antibodies. At present, companies are expanding their businesses to increase the development and sales of monoclonal antibodies. Technavio's analysts have predicted that the monoclonal antibodies market will register a CAGR of about 15% by 2022.

Market Overview:

Introduction of low cost biosimilar monoclonal antibodies

The introduction of biosimilars aimed at curbing the increasing year-over-year cost of healthcare and handling the economic pressure from the patient pool and governments to reduce healthcare expenses, could be instrumental in reducing the cost of medication and increasing patient access to treatment.

High cost of monoclonal antibodies

Monoclonal antibodies cost high, both at end-user stage as well as the development stage, primarily owing to the use of highly advanced and expensive facilities.

For the detailed list of factors that will drive and challenge the growth of the monoclonal antibodies market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Johnson & Johnson and Merck the competitive environment is quite intense. Factors such as the rise in the number of companies venturing into monoclonal antibodies space and the introduction of low cost biosimilar monoclonal antibodies, will provide considerable growth opportunities to monoclonal antibodies manufactures. AbbVie, Amgen, Johnson & Johnson, and Merck are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY APPLICATION

  • Segmentation by application
  • Comparison by application
  • Oncology - Market size and forecast 2017-2022
  • Immunology - Market size and forecast 2017-2022
  • Hematology - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by application

PART 09: MARKET SEGMENTATION BY ORIGIN OF MONOCLONAL ANTIBODIES

  • Segmentation by origin of monoclonal antibodies
  • Murine antibodies
  • Human antibodies
  • Humanized antibodies
  • Chimeric antibodies

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • Increasing cases of diseases like cancer and immunological disorders
  • Rise in the number of companies venturing into the monoclonal antibodies space
  • Growing pricing pressure in the monoclonal antibodies segment

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Merck

PART 17: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Monoclonal antibodies in the pipeline
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global monoclonal antibodies market - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 10: Global monoclonal antibodies market - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Global monoclonal antibodies market by application - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by application
  • Exhibit 21: List of monoclonal antibodies approved by FDA/European Medicines Agency post 2015
  • Exhibit 22: Oncology - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 23: Oncology - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Sales of monoclonal antibodies in oncology ($ mn)
  • Exhibit 25: Immunology - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 26: Sales of monoclonal antibodies for immunology ($ mn)
  • Exhibit 27: Immunology - Year-over-year growth 2018-2022 (%)
  • Exhibit 28: Hematology - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 29: Hematology - Year-over-year growth 2018-2022 (%)
  • Exhibit 30: Others - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 31: Sales of monoclonal antibodies in the others segment ($ mn)
  • Exhibit 32: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 33: Market opportunity by application
  • Exhibit 34: Customer landscape
  • Exhibit 35: Global monoclonal antibodies market by geography - Market share 2017-2022 (%)
  • Exhibit 36: Regional comparison
  • Exhibit 37: Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 38: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 39: Top 3 countries in Americas
  • Exhibit 40: EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 41: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 42: Top 3 countries in EMEA
  • Exhibit 43: APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 44: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 45: Top 3 countries in APAC
  • Exhibit 46: Market opportunity
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: AbbVie: An overview
  • Exhibit 52: AbbVie - Business segments
  • Exhibit 53: AbbVie - Organizational developments
  • Exhibit 54: AbbVie - Geographic focus
  • Exhibit 55: AbbVie - Segment focus
  • Exhibit 56: AbbVie - Key offerings
  • Exhibit 57: Amgen: An overview
  • Exhibit 58: Amgen - Business segments
  • Exhibit 59: Amgen - Organizational developments
  • Exhibit 60: Amgen - Geographic focus
  • Exhibit 61: Amgen - Segment focus
  • Exhibit 62: Amgen - Key offerings
  • Exhibit 63: Johnson & Johnson: An overview
  • Exhibit 64: Johnson & Johnson - Business segments
  • Exhibit 65: Johnson & Johnson - Organizational developments
  • Exhibit 66: Johnson & Johnson - Geographic focus
  • Exhibit 67: Johnson & Johnson - Segment focus
  • Exhibit 68: Johnson & Johnson - Key offerings
  • Exhibit 69: Merck: An overview
  • Exhibit 70: Merck - Business segments
  • Exhibit 71: Merck - Organizational developments
  • Exhibit 72: Merck - Geographic focus
  • Exhibit 73: Merck - Segment focus
  • Exhibit 74: Merck - Key offerings
Back to Top